CD274 and neoplasm: With respect to immunotherapy using PD-1 or PD-L1 inhibitors for primary hepatic SCC, Chan KK et al. reported a case where genetic testing revealed PD-L1 Tumor Proportion Score (TPS) of 1%, a Tumor Mutational Burden (TMB) of 24.93 mutations/Mb, a Genomic Profiling Score (GPS) of 1, and Microsatellite Instability-High (MSI-H).